Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. University of Athens School of Medicine, Athens, Greece

Survival: 18.0 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: Greece
City/State/Province: Athens
Hospital: University of Athens School of Medicine
Journal: Link
Date: 1/2004

Patients: This Phase II study involved 38 patients with hormone refractory prostate cancer. Patients were divided into two groups: Group 1 and Group 2. The average age of patients in Group 2 was 74 and the median PSA was 103 .5 (range from 8.5 4290).

Treatment: Patients in Group 2 were treated with a somatostatin analogue (lanreotide, somatuline), dexamethasone and orchiectomy or the LHRH (lutenizing hormone-releasing hormone) analog triptorelin (arvekap).

Toxicity: For patients in Group 2, grade 2-3 toxicities included anemia, fluid retention, and elevated blood glucose.

Results: The median overall survival for patients in Group 2 was 18 months.

Correspondence: M.A. Dimopoulos, MD

E-mail to a Friend More Information